Clinical Trial Update: Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating CMV-specific CD19-CAR T-cells in combination with the CMV-MVA Triplex vaccine for intermediate- or high-grade B-cell non-Hod…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• High-grade B-cell Non-hodgkin Lymphoma
• Intermediate-grade B-cell Non-hodgkin Lymphoma

Drugs mentioned

• CMV-MVA Triplex Vaccine (CMV-MVA Triplex Vaccine)
• CMV-Specific CD19-CAR T-cells

Snippet

Sponsor: City of Hope Medical Center | Conditions: High Grade B-Cell Non-Hodgkin's Lymphoma, Intermediate Grade B-Cell Non-Hodgkin's Lymphoma | Phase 1 | Status: RECRUITING